NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Forecast, Price & News

$3.14

+0.11 (+3.63%)

(As of 06/9/2023 ET)

Compare

Today's Range: $3.00
▼
$3.19
50-Day Range: $2.64
▼
$3.48
52-Week Range: $1.81
▼
$5.65

Volume: 360,551 shs
Average Volume: 302,178 shs
Market Capitalization: $397.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.05

Compass Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.0% Downside
$0.00 Price Target
Short Interest: Healthy
3.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.19
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$33,700 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.34) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

179th out of 988 stocks

Biological Products, Except Diagnostic Industry

24th out of 161 stocks

0.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $0.00, Compass Therapeutics has a forecasted downside of 100.0% from its current price of $3.14.
Amount of Analyst Coverage
Compass Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.05% of the float of Compass Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Compass Therapeutics has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Compass Therapeutics has recently decreased by 5.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Compass Therapeutics does not currently pay a dividend.
Dividend Growth
Compass Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMPX.

2.9

News and Social Media Coverage

News Sentiment
Compass Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Compass Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,700.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.27% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.34) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Compass Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Compass Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Compass Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Compass Therapeutics (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMPX Stock News Headlines

June 3, 2023 | americanbankingnews.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $9.05 Consensus Price Target from Analysts

June 1, 2023 | finance.yahoo.com

Compass Therapeutics to Participate in Upcoming Investor Events

June 10, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

June 1, 2023 | americanbankingnews.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Decline in Short Interest

May 31, 2023 | americanbankingnews.com

Head-To-Head Contrast: argenx (NASDAQ:ARGX) vs. Compass Therapeutics (NASDAQ:CMPX)

May 11, 2023 | americanbankingnews.com

Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $9.05

May 10, 2023 | americanbankingnews.com

FY2027 EPS Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX) Lifted by Wedbush

May 10, 2023 | americanbankingnews.com

Head to Head Review: BioAtla (NASDAQ:BCAB) vs. Compass Therapeutics (NASDAQ:CMPX)

June 10, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: See The True Value of Any Stock

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 10, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)

May 9, 2023 | americanbankingnews.com

HC Wainwright Equities Analysts Raise Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX)

May 4, 2023 | msn.com

Compass Therapeutics: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

April 26, 2023 | finance.yahoo.com

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 25, 2023 | usnews.com

Frequently Asked Questions: U.S. News College Compass

April 19, 2023 | finance.yahoo.com

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 16, 2023 | americanbankingnews.com

Compass Therapeutics (NASDAQ:CMPX) vs. Sutro Biopharma (NASDAQ:STRO) Financial Comparison

April 16, 2023 | americanbankingnews.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of "Buy" from Brokerages

April 13, 2023 | finance.yahoo.com

With 55% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners

March 31, 2023 | americanbankingnews.com

Financial Review: Valneva (NASDAQ:VALN) & Compass Therapeutics (NASDAQ:CMPX)

March 28, 2023 | finance.yahoo.com

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

March 22, 2023 | americanbankingnews.com

SVB Leerink Equities Analysts Boost Earnings Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX)

March 21, 2023 | americanbankingnews.com

Equities Analysts Issue Forecasts for Compass Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CMPX)

March 21, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Compass Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CMPX)

March 17, 2023 | seekingalpha.com

Compass Therapeutics GAAP EPS of -$0.10

March 17, 2023 | finance.yahoo.com

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

March 15, 2023 | finance.yahoo.com

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

See More Headlines

CMPX Price History

30 days | 90 days | 365 days | Advanced Chart

CMPX Company Calendar

Last Earnings: 3/15/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CMPX
CUSIP: N/A
CIK: 1738021
Web: www.compasstherapeutics.com
Phone: 617-500-8099
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $0.00
High Stock Price Forecast: $0.00
Low Stock Price Forecast: $10,000,000.00
Forecasted Upside/Downside: +188.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,220,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.60%
Return on Assets: -24.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.41
Quick Ratio: 16.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.44 per share
Price / Book: 2.18

Miscellaneous

Outstanding Shares: 126,510,000
Free Float: 88,808,000
Market Cap: $397.24 million
Optionable: Not Optionable
Beta: 0.71

Key Executives

Dr. Thomas J. Schuetz M.D. (Age 62)
Ph.D., Co-Founder, CEO & Director
Comp: $829.56k

Dr. Vered Bisker-Leib M.D. (Age 51)
MBA, Ph.D., Pres & COO
Comp: $806.43k

Mr. Neil L. Lerner CPA (Age 56)
VP of Fin.

Mr. Jonathan Anderman J.D.
VP, Head of Legal & Corp. Sec.

Anna Gifford
Communications Mang.

Dr. Minori Rosales M.D. (Age 60)
Ph.D., Sr. VP & Head of Clinical Devel.

Ms. Karin Herrera B.A.
VP & Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CMPX Stock - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?: 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" CMPX shares.
View CMPX analyst ratings or view top-rated stocks.
What is Compass Therapeutics' stock price forecast for 2023?: 0 Wall Street analysts have issued 12-month target prices for Compass Therapeutics' stock. Their CMPX share price forecasts range from $10,000,000.00 to $0.00. On average, they expect the company's share price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for CMPX or view top-rated stocks among Wall Street analysts.
How have CMPX shares performed in 2023?: Compass Therapeutics' stock was trading at $5.03 at the beginning of the year. Since then, CMPX stock has decreased by 37.6% and is now trading at $3.14.
View the best growth stocks for 2023 here.
When is Compass Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our CMPX earnings forecast.
How were Compass Therapeutics' earnings last quarter?: Compass Therapeutics, Inc. (NASDAQ:CMPX) released its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01.
When did Compass Therapeutics IPO?: (CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

What is Compass Therapeutics' stock symbol?: Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX."
Who are Compass Therapeutics' major shareholders?: Compass Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.49%), Foresite Capital Management V LLC (2.75%), Braidwell LP (2.57%), Monashee Investment Management LLC (1.72%), BlackRock Inc. (1.22%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends.
How do I buy shares of Compass Therapeutics?: Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Compass Therapeutics' stock price today?: One share of CMPX stock can currently be purchased for approximately $3.14.
How much money does Compass Therapeutics make?: Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $397.24 million. The company earns $-39,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.
How can I contact Compass Therapeutics?: The official website for the company is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com.

This page (NASDAQ:CMPX) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial